SQI Diagnostics Inc V.SQD.H

Healthcare Medical Devices

SQI Diagnostics Inc. is a Canada-based company that is focused on lung health. The Company is engaged in the development and manufacturing of respiratory health and precision medicine tests that run on its fully automated systems. Its clinical solutions include Rapid Acute Lung Injury Diagnostic (RALI-Dx), lung transplant diagnostics, COVID-19 testing and surveillance testing solutions. Its RALI-Dx IL-6 Severity Triage Test and the RALI-fast IL-6 Severity Triage point of care (POC) Test each help clinicians identify which patients with SARS-CoV-2 are predicted to have a severe inflammatory response and should or should not be admitted to the hospital. Its RALI-Dx delivers results from the lab in less than an hour while RALI-fast delivers results at the patient point-of-care in about 15 minutes. The Company’s TORdx LUNG Test measures inflammation at the molecular level to assess the health of the donor lung. The Company is also focused on its organ transplant pipeline of products.

TSXV:SQD.H - Post by User

SQI Diagnostics Inc > RALI-Dx™ Severity/Triage Tests

<< Previous

Bullboard Posts

Next >>

Comment by mercedesmanon Nov 02, 2022 10:02am

95 Views

Post# 35065991

RE:RALI-Dx™ Severity/Triage Tests

SQIReader wrote: Monitoring of patients in the ICU > 25 million ICU Patient Days in North America > 60% Respiratory involvement

25 million X 60 % = $15,000,000 patients

X $400 per test

= 6 Billion and that's just north america - the plan is emergency rooms world wide

Agree...large potential...BUT...

What is the plan to get FDA approval, before it can be used in the US ? Has anything been submitted? If not, when?

What's the European regulatory hurdle like?

Alongside, of course, a commercialization/rollout plan for Canada.

MM

<< Previous

Bullboard Posts

Next >>

High-growth stock Happy Belly opens first Rosie's Burgers in Alberta